ArticleGynecologic oncology reports2025
Impact of lymph node staging techniques on lymphedema and quality of life in early-stage endometrial cancer: A prospective cohort study.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sentinel lymph node (SLN) biopsy is increasingly replacing complete pelvic lymphadenectomy (CL) for staging early-stage endometrial cancer (EC), but its long-term impact on patients' quality of life (QoL) and lymphedema remains underexplored. Objective: To compare overall health perception (oHP), health-related QoL (HRQoL), and symptomatic lymphedema in patients staged with SLN versus CL. Secondary objectives included the assessment of symptomatic lymphedema and surgical complications. Methods: We conducted a prospective single-center observational study including 97 patients treated early-stage EC, with 50 undergoing SLN plus CL and 47 undergoing SLN only. Patients completed EQ-5D-3L, oHP scale (0-100), and the self-reported lower-extremity lymphedema questionnaire (LELQ) at baseline and 6-month follow-up. Multivariate analysis adjusted for confounders including surgical approach and adjuvant therapy. Results: At 6 months, the SLN group reported significantly better oHP (median 85 vs. 70; p = 0.001) and HRQoL impairment (median score 5 vs. 7; p = 0.001) than the CL group. Symptomatic lymphedema (LELQ > 5) was significantly lower in the SLN group (7.0 %) than in the CL group (34.4 %, p = 0.002). No significant differences in intra- or postoperative complications were observed. Conclusion: SLN biopsy was associated with improved QoL and lower incidence of lymphedema compared to complete lymphadenectomy. These findings support the use of SLN mapping as the preferred nodal staging technique to minimize morbidity and enhance survivorship outcomes in early-stage EC patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.